Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
1.550
-0.120 (-7.19%)
At close: Nov 26, 2025, 4:00 PM EST
1.560
+0.010 (0.65%)
After-hours: Nov 26, 2025, 7:23 PM EST
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 11 or 55.00% compared to the previous year.
Employees
31
Change (1Y)
11
Growth (1Y)
55.00%
Revenue / Employee
n/a
Profits / Employee
-$2,666,742
Market Cap
116.48M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31 | 11 | 55.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 5 | 41.67% |
| Dec 31, 2021 | 12 | 2 | 20.00% |
| Dec 31, 2020 | 10 | 2 | 25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELDN News
- 9 days ago - Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - GlobeNewsWire
- 10 days ago - Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 13 days ago - Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results - GlobeNewsWire
- 15 days ago - Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 16 days ago - Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 20 days ago - Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript - Seeking Alpha
- 20 days ago - Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study - Benzinga
- 21 days ago - Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting - GlobeNewsWire